LEK D D Pakirni Center Lendava Trimlini Pharmaceutical Import Profile — Slovenia (DGFT 2022–2026)

Name: LEK D D Pakirni Center Lendava Trimlini Pharmaceutical Import Records from India — 2 Products, $1.2M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

LEK D D Pakirni Center Lendava Trimlini — Pharmaceutical Importer Profile (2026) | 2 Products, $1.2M Trade | TransData Nexus

LEK D D Pakirni Center Lendava Trimlini

Pharmaceutical Importer · Slovenia · Immunosuppressants Focus · $1.2M Total Trade · DGFT Verified

LEK D D Pakirni Center Lendava Trimlini is a pharmaceutical importer based in Slovenia with a total trade value of $1.2M across 2 products in 2 therapeutic categories. Based on 24 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. LEK D D Pakirni Center Lendava Trimlini sources from 1 verified Indian supplier, with Sandoz Private Limited accounting for 100.0% of imports.

LEK D D Pakirni Center Lendava Trimlini — Import Portfolio & Supplier Network

LEK D D Pakirni Center Lendava Trimlini import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to LEK D D Pakirni Center Lendava Trimlini?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Sandoz Private Limited	$3.8M	92	100.0%

LEK D D Pakirni Center Lendava Trimlini sources from 1 verified Indian supplier across 55 distinct formulations. The sourcing is highly concentrated — Sandoz Private Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

What Formulations Does LEK D D Pakirni Center Lendava Trimlini Import?

Formulation	Value	Ships
Gabapentin hgc 300MG in91 sh eu 03 material no. -	$400.0K	8
Mycophen mof hgc 250MG in91 sh eu 05 material no. -	$150.0K	3
Tacrolimus hgc 5MG in91 sh eu 03 material no. -	$150.0K	3
Tacrolimus hgc 1MG in91 sh eu 04 material no. -	$150.0K	3
Gabapentin hgc 100MG in91 sh eu 03 material no. -	$111.7K	4
Material no. - 42028358 gabapentin hgc 100MG in91 sh eu	$108.7K	3
Valsart+hct fct 160+12.5MG in91 sh eu 03material no. -	$100.0K	2
Tacrolimus hgc 1MG in91 sh eu 05 material no. -	$100.0K	2
Desloratadine fct 5MG in91 sh eu 07 material no. -	$100.0K	2
Clopidogrel hcl fct 75MG in91 sh eu 04 material no. -	$100.0K	2
Material no. - 42026721 voriconazole fct200mg in91 sh	$100.0K	2
Allopurinol TAB 300MG in91 sh eu 02 material no. -	$100.0K	2
Material no. - 42031824 desloratadine fct 5MG in91 sh eu	$100.0K	2
Material no. - 42001133 fluvastatin sodprt 80MG in91 sh	$100.0K	2
Valsartan fct 320MG in91 sh eu 03 material no. -	$99.5K	2

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Tacrolimus	Immunosuppressants	$1.0M	20	0.5%	11
2	Loratadine	Antihistamines & Allergy	$200.0K	4	0.1%	18

LEK D D Pakirni Center Lendava Trimlini imports 2 pharmaceutical products across 2 categories into Slovenia totaling $1.2M.

LEK D D Pakirni Center Lendava Trimlini — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

LEK D D Pakirni Center Lendava Trimlini is a pharmaceutical importer and buyer based in Slovenia, specializing in the procurement of finished pharmaceutical formulations. The company operates under the umbrella of Lek Pharmaceuticals d.d., a subsidiary of Sandoz Pharmaceuticals, a global leader in generic pharmaceuticals. Lek Pharmaceuticals d.d. is headquartered in Ljubljana, Slovenia, and has a significant manufacturing facility in Lendava, located at Trimlini 2D, 9220 Lendava. (bizi.si)

As a key player in Slovenia's pharmaceutical distribution network, LEK D D Pakirni Center Lendava Trimlini plays a crucial role in ensuring the availability of essential medications within the country. The company's operations are integral to Lek Pharmaceuticals d.d.'s broader mission of developing, producing, and distributing high-quality, affordable pharmaceuticals to improve patient outcomes. (dcs.si)

2Distribution Network

LEK D D Pakirni Center Lendava Trimlini's distribution network is centered around its facility in Lendava, Slovenia. The Lendava site serves as a strategic hub for the company's operations, facilitating efficient logistics and distribution within Slovenia and to neighboring regions. The facility's location at Trimlini 2D, 9220 Lendava, positions it advantageously for regional distribution, leveraging Slovenia's well-developed transportation infrastructure. (bizi.si)

While specific details about additional warehouse locations and logistics capabilities are not publicly disclosed, the Lendava facility's strategic positioning suggests a focus on optimizing supply chain efficiency and ensuring timely delivery of pharmaceutical products across Slovenia and potentially to other European markets.

3Industry Role

LEK D D Pakirni Center Lendava Trimlini functions primarily as a pharmaceutical importer and buyer within Slovenia's pharmaceutical supply chain. Its role involves sourcing finished pharmaceutical formulations from international suppliers, particularly from India, and facilitating their distribution within Slovenia. This position is critical in ensuring the availability of a diverse range of medications to meet the healthcare needs of the Slovenian population.

The company's operations are closely integrated with Lek Pharmaceuticals d.d.'s manufacturing and distribution activities, contributing to the overall efficiency and effectiveness of the pharmaceutical supply chain in Slovenia. By importing and distributing essential pharmaceutical products, LEK D D Pakirni Center Lendava Trimlini supports the broader mission of providing high-quality, affordable healthcare solutions to patients.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — LEK D D Pakirni Center Lendava Trimlini

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

LEK D D Pakirni Center Lendava Trimlini demonstrates a high degree of supplier concentration, sourcing 100% of its pharmaceutical imports from a single supplier, Sandoz Private Limited. This exclusive sourcing strategy indicates a strategic partnership, likely aimed at ensuring consistent quality, reliability, and favorable pricing for the imported products.

The shipment data reveals a stable and ongoing relationship between LEK D D Pakirni Center Lendava Trimlini and Sandoz Private Limited, with 24 shipments recorded over the period from 2022 to 2026. This consistency suggests a well-established and dependable supply chain, minimizing potential disruptions and facilitating efficient inventory management.

However, the single-source dependency also presents potential risks, such as vulnerability to supply chain disruptions or changes in supplier terms. To mitigate these risks, LEK D D Pakirni Center Lendava Trimlini may consider diversifying its supplier base or establishing contingency plans to ensure continuity of supply in unforeseen circumstances.

2Supply Chain Resilience

The resilience of LEK D D Pakirni Center Lendava Trimlini's supply chain is closely tied to its exclusive sourcing arrangement with Sandoz Private Limited. While this partnership offers benefits such as consistent product quality and reliable delivery schedules, it also means that the company's supply chain is highly dependent on a single supplier.

Importing Pharmaceuticals into Slovenia — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Slovenia

1Regulatory Authority & Framework

In Slovenia, the Agency for Medicinal Products and Medical Devices (JAZMP) serves as the primary regulatory authority overseeing the pharmaceutical sector. JAZMP is responsible for ensuring the safety, efficacy, and quality of medicinal products available in the Slovenian market. The agency's role encompasses the evaluation and approval of marketing authorizations, monitoring of adverse drug reactions, and enforcement of compliance with pharmaceutical regulations.

Key legislation governing pharmaceutical imports into Slovenia includes the Medicinal Products Act, which outlines the requirements for the importation, distribution, and marketing of medicinal products. This act aligns with European Union directives, ensuring that imported pharmaceuticals meet the stringent standards set by the European Medicines Agency (EMA). The marketing authorization pathway for Indian generics involves a thorough evaluation by JAZMP, including assessments of quality, safety, and efficacy, to ensure that imported generics are equivalent to their reference products.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products in Slovenia are stringent, necessitating that all imported medicines possess a valid marketing authorization issued by JAZMP. This authorization confirms that the product complies with Slovenian and EU regulations concerning quality, safety, and efficacy. Additionally, importers must ensure that their suppliers hold Good Manufacturing Practice (GMP) certificates recognized by the European Union, such as EU GMP, WHO GMP, or PIC/S certifications.

LEK D D Pakirni Center Lendava Trimlini — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

LEK D D Pakirni Center Lendava Trimlini's focus on importing immunosuppressants and antihistamines aligns with the therapeutic needs of the Slovenian population. Immunosuppressants are critical for patients undergoing organ transplants or receiving treatment for autoimmune disorders, while antihistamines address common allergic reactions. The market demand for these products is driven by the prevalence of chronic conditions requiring long-term management and the need for effective treatments for allergic responses.

The company's import strategy, emphasizing these therapeutic areas, reflects a commitment to providing essential medications that address significant health concerns within Slovenia. By focusing on these categories, LEK D D Pakirni Center Lendava Trimlini ensures that it meets the ongoing demand for these critical treatments, contributing to improved patient outcomes and quality of life.

2Sourcing Profile

LEK D D Pakirni Center Lendava Trimlini's sourcing strategy is centered on importing generic pharmaceutical formulations from India, particularly from Sandoz Private Limited. This approach leverages India's robust pharmaceutical manufacturing capabilities, which are recognized for producing high-quality generics at competitive prices. The focus on finished pharmaceutical formulations, rather than raw APIs or bulk drugs, indicates a strategic decision to streamline the supply chain and ensure the availability of ready-to-use medications.

Frequently Asked Questions — LEK D D Pakirni Center Lendava Trimlini

What products does LEK D D Pakirni Center Lendava Trimlini import from India?

LEK D D Pakirni Center Lendava Trimlini imports 2 pharmaceutical products across 2 categories. Top imports: Tacrolimus ($1.0M), Loratadine ($200.0K).

Who supplies pharmaceuticals to LEK D D Pakirni Center Lendava Trimlini from India?

LEK D D Pakirni Center Lendava Trimlini sources from 1 verified Indian suppliers. The primary supplier is Sandoz Private Limited (100.0% of imports, $3.8M).

What is LEK D D Pakirni Center Lendava Trimlini's total pharmaceutical import value?

LEK D D Pakirni Center Lendava Trimlini's total pharmaceutical import value from India is $1.2M, based on 24 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does LEK D D Pakirni Center Lendava Trimlini focus on?

LEK D D Pakirni Center Lendava Trimlini imports across 2 categories. The largest: Immunosuppressants (83.3%), Antihistamines & Allergy (16.7%).

Get Full LEK D D Pakirni Center Lendava Trimlini Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.